How stress responses affect tumor growth in lung cancer with EGFR mutations
Stress responses drive resistance and shape tumor evolution in EGFR mutant lung cancer
This study is looking at how stress in lung cancer cells can make them tougher against treatments, specifically for patients with a certain type of lung cancer caused by EGFR mutations, to help find better ways to fight the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10771103 on NIH RePORTER |
What this research studies
This research investigates how stress responses in tumor cells contribute to resistance against targeted therapies in patients with EGFR-mutant lung cancer. By examining the mechanisms behind tumor cell persistence and drug tolerance, the study aims to understand how these stress signals influence tumor evolution after treatment. The researchers will utilize patient tumor samples and advanced laboratory techniques to explore the relationship between stress signaling and acquired resistance to EGFR inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with EGFR-mutant non-small cell lung cancer who are undergoing treatment with EGFR tyrosine kinase inhibitors.
Not a fit: Patients with lung cancer that does not have EGFR mutations or those who are not receiving targeted therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve treatment outcomes for patients with EGFR-mutant lung cancer.
How similar studies have performed: Previous research has shown promising results in understanding tumor resistance mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Bivona, Trever G — University of California, San Francisco
- Study coordinator: Bivona, Trever G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.